MedTrace Logo

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

NCT03347253 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-07-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) subjects receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained may be used in the design and conduct of future studies in LOPD subjects.

Conditions

  • Late-onset Pompe Disease

Sponsors & Collaborators

  • Amicus Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-08
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States
  • Australia
  • Belgium
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03347253 on ClinicalTrials.gov